Advertisement

Interstitial Lung Disease in Elderly Rheumatoid Arthritis Patients

  • Riccardo Messina
  • Giuliana Guggino
  • Alida Benfante
  • Nicola ScichiloneEmail author
Therapy in Practice
  • 37 Downloads

Abstract

The increase in life expectancy together with better care of rheumatoid arthritis (RA) has led to higher proportions of elderly individuals with RA. This has challenged the treatment of the disease in older aged patients, usually characterized by comorbid conditions and polypharmacy. Overall, the lung involvement in RA is present in up to 80% of patients, depending on the assessment tools used, and interstitial abnormalities are among the most common; when present, interstitial lung disease (ILD) worsens the prognosis of RA, and is the second most common cause of mortality. The aged lung undergoes functional and structural changes termed immunosenescence and inflammaging, which facilitate the occurrence of fibrosis of the lung. Therefore, ILD tends to occur more frequently in older patients with RA. The age at onset of RA distinguishes patients as having young-onset RA (YORA, < 60 years) or late-onset RA (LORA, > 60 years); the latter are characterized by more severe features of the disease and higher rates of lung involvement. The most frequent RA-related ILD radiological pattern is usual interstitial pneumonia (UIP); this includes peripheral and basal predominant reticulation and honeycombing with or without associated traction bronchiectasis. Patients with the UIP pattern are usually older and have more rapid decline in lung function and a worse prognosis. Treatment with corticosteroids in elderly patients carries the risk of adverse effects, such as osteoporosis, infections, diabetes, peptic ulcers, and cataract. The use of disease-modifying antirheumatic drugs (DMARDs) is generally well-tolerated by the elderly. The current narrative review aims at elucidating the association between ILD and RA in older individuals.

Notes

Compliance with Ethical Standards

Funding

None.

Conflict of interest

RM, GG, AB, and NS have no conflicts of interest to declare.

References

  1. 1.
    Cortet B, Perez T, Roux N, Flipo RM, Duquesnoy B, Delcambre B, et al. Pulmonary function tests and high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis. 1997;56:596–600.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Balbir-Gurman A, Yigla M, Nahir AM, et al. Rheumatoid pleural effusion. Semin Arthritis Rheum. 2006;35:368–78.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Corcoran JP, Ahmad M, Mukherjee R, et al. Pleuro-pulmonary complications of rheumatoid arthritis. Respir Care. 2014;59:55–9.CrossRefGoogle Scholar
  4. 4.
    Yunt ZX, Solomon JJ. Lung disease in rheumatoid arthritis. Rheum Dis Clin N Am. 2015;41(2):225–36.CrossRefGoogle Scholar
  5. 5.
    Spagnolo Paolo, Lee Joyce S, Sverzellati Nicola, Rossi Giulio, Cottin Vincent. The lung in rheumatoid arthritis: focus on interstitial lung disease. Arthritis Rheumatol. 2018;70(10):1544–54.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Marigliano B, Soriano A, Margiotta D, Vadacca M, Afeltra A. Lung involvement in connective tissue diseases: a comprehensive review and a focus on rheumatoid arthritis. Autoimmun Rev. 2013;12:1076–84.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology (Oxford). 2017;56:344–50.Google Scholar
  8. 8.
    O’Dwyer DN, Armstrong ME, Cooke G, et al. Rheumatoid arthritis (RA) associated interstitial lung disease (ILD). Eur J Intern Med. 2013;24:597–603.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Lee HK, Kim DS, Yoo B, Seo JB, Rho JY, Colby TV, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127:2019–27.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Selman M, López-Otín C, Pardo A. Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir J. 2016;48(2):538–52.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Miller MR. Structural and physiological age-associated changes in aging lungs. Semin Respir Crit Care Med. 2010;31(5):521–7.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Sorino C, Battaglia S, Scichilone N, Pedone C, Antonelli-Incalzi R, Sherrill D, Bellia V. Diagnosis of airway obstruction in the elderly: contribution of the SARA study. Int J Chronic Obstr Pulm Dis. 2012;7:389–95.CrossRefGoogle Scholar
  13. 13.
    Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet. 2010;376:803–13.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology. 2007;120:435–46.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Murtha LA, Morten M, Schuliga MJ, Mabotuwana NS, Hardy SA, Waters DW. The role of pathological aging in cardiac and pulmonary fibrosis. Aging Dis. 2019;10(2):419–28.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Bueno M, Lai YC, Romero Y, Brands J, St Croix CM, Kamga C, et al. PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis. J Clin Investig. 2015;125(2):521–38.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Sueblinvong V, Neujahr DC, Mills ST, Roser-Page S, Ritzenthaler JD, Guidot D, et al. Predisposition for disrepair in the aged lung. Am J Med Sci. 2012;344(1):41–51.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Sihvonen S. Mortality and causes of death in patients with rheumatoid arthritis. Scand J Reumatol. 2004;33:221–7.CrossRefGoogle Scholar
  19. 19.
    Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, Dixey J, Early Rheumatoid Arthritis Study (ERAS) group. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford). 2007;46(2):350–7.CrossRefGoogle Scholar
  20. 20.
    Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583–91.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon JJ, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011;183:372–8.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Shaw M, Collins BF, Ho LA, Raghu G. Rheumatoid arthritis-related interstitial lung disease. Eur Respir Rev. 2015;24:1–16.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    van der Heijde DM, van Riel PL, van Leeuwen MA, van’t Hof MA, van Rijswijk MH, van de Putte LB. Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis. J Rheumatol. 1991;18(9):1285–9.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Deal CL, Meenan RF, Goldenberg DL, Anderson JJ, Sack B, Pastan RS, Cohen AS. The clinical features of elderly-onset rheumatoid arthritis. A comparison with younger-onset disease of similar duration. Arthritis Rheum. 1985;28(9):987–94.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Pease CT, Bhakta BB, Devlin J, Emery P. Does the age of onset of rheumatoid arthritis influence phenotype? A prospective study of outcome and prognostic factors. Rheumatology (Oxford). 1999;38(3):228–34.CrossRefGoogle Scholar
  26. 26.
    Mueller RB, Kaegi T, Finckh A, Haile SR, Schulze-Koops H, von Kempis J. Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort. Rheumatology (Oxford). 2013;53(4):671–7.CrossRefGoogle Scholar
  27. 27.
    Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35:1322–8.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Gabbay E, Tarala R, Will R, Carroll G, Adler B, Cameron D, et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med. 1997;156:528–35.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Habib HM, Eisa AA, Arafat WR, Marie MA. Pulmonary involvement in early rheumatoid arthritis patients. Clin Rheumatol. 2011;30:217–21.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Saag KG, Kolluri S, Koehnke RK, Georgou TA, Rachow JW, Hunninghake GW, et al. Rheumatoid arthritis lung disease: determinants of radiographic and physiologic abnormalities. Arthritis Rheum. 1996;39:1711–9.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    De Lauretis A, Veeraraghavan S, Renzoni E. Review series: aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chronic Respir Dis. 2011;8:53–82.CrossRefGoogle Scholar
  32. 32.
    Myasoedova E, Crowson CS, Turesson C, Gabriel SE, Matteson EL. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995–2007 versus 1985–1994: a population-based study. J Rheumatol. 2011;38:983–9.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med. 2012;106:1591–9.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Hozumi H, Nakamura Y, Johkoh T, Sumikawa H, Colby TV, Kono M, et al. Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open. 2013;3:e003132.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Rajasekaran BA, Shovlin D, Lord P, Kelly CA. Interstitial lung disease in patients with rheumatoid arthritis: a comparison with cryptogenic fibrosing alveolitis over 5 years. Rheumatology (Oxford). 2001;40:1022–5.CrossRefGoogle Scholar
  36. 36.
    Udayakumar N, Venkatesan S, Rajendiran C. Pulmonary hypertension in rheumatoid arthritis—relation with the duration of the disease. Int J Cardiol. 2008;127(3):410–2.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Solomon JJ, Ryu JH, Tazelaar HD, Myers JL, Tuder R, Cool CD, et al. Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RAILD). Respir Med. 2013;107:1247–52.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Ciancio N, Pavone M, Torrisi SE, Vancheri A, Sambataro D, Palmucci S, et al. Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases. Multidiscip Respir Med. 2019;14:17.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med. 2003;168:531–7.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63:58.Google Scholar
  41. 41.
    Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009;136:1397–405.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165:1581–6.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Huh JW, Kim DS, Lee CK, Yoo B, Bum Seo J, Kitaichi M, et al. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respir Med. 2007;101:1761–9.CrossRefGoogle Scholar
  44. 44.
    Nurmi HM, Purokivi MK, Karkkainen MS, Kettunen HP, Selander TA, Kaarteenaho RL. Variable course of disease of rheumatoid arthritis-associated usual interstitial pneumonia compared with other subtypes. BMC Pulm Med. 2016;16:107.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Koduri G, Norton S, Young A, Cox N, Davies P, Devlin J, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford). 2010;49:1483–9.CrossRefGoogle Scholar
  46. 46.
    Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2016;47:588–96.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Walsh SL, Sverzellati N, Devaraj A, Keir GJ, Wells AU, Hansell DM. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax. 2014;69:216–22.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Cottin V, Cordier JF. Combined pulmonary fibrosis and emphysema in connective tissue disease. Curr Opin Pulm Med. 2012;18:418–27.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory statement: update of the international multidisciplinary classification of the idiopathic pneumonias. Am J Respir Crit Care Med. 2013;188:733–48.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Mathai S, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;352:h6819.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976–87.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Levi Y, Israeli-Shani L, Kuchuk M, Epstein Shochet G, Matthew Koslow M, David Shitrit D. Rheumatological assessment is important for interstitial lung disease diagnosis. J Rheumatol. 2018;45(11):1509–14.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Walsh SLF. Multidisciplinary evaluation of interstitial lung diseases: current insights. Eur Respir Rev. 2017;26(144):170002.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Innala L, Berglin E, Möller B, Ljung L, Smedby T, Södergren A, et al. Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2014;16(2):R94.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Villa-Blanco JI, Calvo-Alén J. Elderly onset rheumatoid arthritis: differential diagnosis and choice of first-line and subsequent therapy. Drugs Aging. 2009;26:739–50.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Tutuncu Z, Kavanaugh A. Rheumatic disease in the elderly: rheumatoid arthritis. Rheum Dis Clin N Am. 2007;33:57–70.CrossRefGoogle Scholar
  57. 57.
    Tutuncu Z, Reed G, Kremer J, Kavanaugh A. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis. 2006;65:1226–9.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Fleischmann RM, Baumgartner SW, Tindall EA, Weaver AL, Moreland LW, Schiff MH, et al. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol. 2003;30(4):691–6.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al. Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007;56(6):1754–64.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968–77.CrossRefGoogle Scholar
  61. 61.
    Nakamura Y, Suda T, Kaida Y, Kono M, Hozumi H, Hashimoto D, et al. Rheumatoid lung disease: prognostic analysis of 54 biopsy-proven cases. Respir Med. 2012;106:1164–9.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Turesson C, Matteson EL, Colby TV, Vuk-Pavlovic Z, Vassallo R, Weyand CM, et al. Increased CD4+ T cell infiltrates in rheumatoid arthritis–associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis Rheum. 2005;52:73–9.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013;40:640–6.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762–84.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Wasko MC, Dasgupta A, Hubert H, Fries JF, Ward MM. Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthrits Rheum. 2013;65(2):334–42.CrossRefGoogle Scholar
  66. 66.
    Barrera P, Laan RF, van Riel PL, Dekhuijzen PN, Boerbooms AM, van de Putte LB. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis. 1994;53(7):434–9.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol. 2014;66(4):803–12.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Grove ML, Hassell AB, Hay EM, Shadforth MF. Adverse reactions to disease-modifying antirheumatic drugs in clinical practice. QJM. 2001;94(6):309–19.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Sathi N, Chikura B, Kaushik VV, Wiswell R, Dawson JK. How common is methotrexate pneumonitis? A large prospective study investigates. Clin Rheumatol. 2012;31(1):79–83.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Alarcon GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case–control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997;127(5):356–64.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Fischer A, Chartrand S. Assessment and management of connective tissue disease-associated interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 2015;32(1):2–21.PubMedPubMedCentralGoogle Scholar
  72. 72.
    Liote H, Liote F, Seroussi B, Mayaud C, Cadranel J. Rituximab-induced lung disease: a systematic literature review. Eur Respir J. 2010;35:681–7.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Md Yusof MY, Kabia A, Darby M, Lettieri G, Beirne P, Vital EM, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years’ experience at a single centre. Rheumatology (Oxford). 2017;56(8):1348–57.CrossRefGoogle Scholar
  74. 74.
    Fui A, Bergantini L, Selvi E, Mazzei MA, Bennett D, Pieroni MG, et al. Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis. Intern Med J. 2019.  https://doi.org/10.1111/imj.14306.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–7.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011;41(2):256–64.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Kurata I, Tsuboi H, Terasaki M, Shimizu M, Toko H, Honda F, et al. Effect of biological disease-modifying anti-rheumatic drugs on airway and interstitial lung disease in patients with rheumatoid arthritis. Intern Med. 2019;58(12):1703–12.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–27.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Solomon JJ, Danoff SK, Goldberg HJ, Woodhead F, Kolb M, Chambers DC, et al. The design and rationale of the Trail1 trial: a randomized double-blind phase 2 clinical trial of pirfenidone in rheumatoid arthritis-associated interstitial lung disease. Adv Ther. 2019;36(11):3279–87.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical SpecialtiesUniversity of PalermoPalermoItaly

Personalised recommendations